-+ 0.00%
-+ 0.00%
-+ 0.00%

Immix Biopharma Reports 75% Complete Response Rate in Phase 2 NXC-201 Trial for Relapsed/Refractory AL Amyloidosis

Reuters·12/07/2025 23:15:17

Please log in to view news